Le Lézard
Classified in: Health, Science and technology, Business
Subject: EARNINGS

Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update


VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announced the financial results for the quarter ended March 31, 2022 and provided a corporate update.

"This quarter marks the first year of operations for Rakovina Therapeutics, Inc. which initiated activity in March 2021," said Mr. Jeffrey Bacha executive chairman of Rakovina Therapeutics, Inc. "We have been pleased with the results of our research as we have conducted parallel drug-discovery and lead optimization activities to characterize three novel small-molecule DNA-damage response (DDR) inhibitor programs with the aim off selecting one or more lead compounds for advancement into human clinical trials."  

"In general, our planned research activities have been completed on, or ahead of schedule ? in spite of some challenges associated with the global pandemic."

Recent Highlights

"Each of these presentations also highlighted that select lead candidates are undergoing evaluation of pharmacokinetics, preliminary safety profile and anti-tumor activity in vivo as an important milestone toward the selection of one or more drug candidates for advancement into human clinical trials," added Mr. Bacha.

Summary Financial Results for the quarter ended March 31, 2022

The Company commenced operations on March 25, 2021, concurrent with the closing of the qualifying transaction with Vincero Capital Corp. and began trading on the Toronto Venture Exchange under the symbol RKV on April 1, 2021. At March 31, 2022, the Company had positive working capital of approximately $2.4 million.

For the three months ending March 31, 2022, the Company reported a net loss of $711,953. Research and development expenses were $456,551 for the three months ended March 31, 2022. General and administrative expenses were $256,996 for the three months ended March 31, 2022. Total cash expenses related to research and development and general and administrative expenses for the three months ended March 31, 2022 were $490,103.


Selected Financial Information
As at
March 31, 2022
$
Cash & cash equivalents2,548,172
Working capital2,470,635
Intangible assets5,455,078
Total Assets8,360,542
Total liabilities434.829
Deficit6,233,105
Total equity7,925,713




Statements
of net loss and comprehensive loss data:
For the three months
ended March 31,

2022
$
Research & Development456,551
General and administrative256,996
Net loss and comprehensive loss711,953
Basic and diluted income (loss) per share(0.01)
Operating cash burn490,103
Weighted average shares outstanding69,826,633


Rakovina Therapeutics' financial statements as filed with SEDAR can be accessed from the Company's website at: https://www.rakovinatherapeutics.com/corporate-profile/

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

Additional Information

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at www.sedar.com.

Contact:

Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: [email protected]
Investor Relations Contact
[email protected]

Media Contact
[email protected]

 



These press releases may also interest you

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...

at 09:38
The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones....

at 09:37
Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China and the United States, today announced it has been granted a new Class III certificate by the National...

at 09:15
101 Mobility® is thrilled to announce the opening of its newest location in Eden Prairie, marking the introduction of the city's first nationally branded full-service provider of a wide range of mobility equipment. This includes stair lifts, ramps,...

at 09:15
Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health.This approval enables Vibrant...

at 09:07
Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the...



News published on and distributed by: